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Abstract 
Background 
The treatment of patients with IMN may include immunomodulation in patients resistant to 
conservative therapy alone, or perceived at high risk of progression.    This study assesses the factors 
influencing the decision to treat with immunomodulators and the choice of treatment between 
alkylating agents and calcineurin inhibitors (CNI). 
Methods 
An inception cohort of 720 adults with biopsy-proven IMN (from 1976-2005) was derived from the 
Glomerular Disease Collaborative Network (N=328) and the Toronto Glomerulonephritis Registry 
(N=392).  Subjects were allocated to groups based on initial treatment: no immunotherapy, alkylating 
agents, CNI, glucocorticoids (GC) only, or other immunosuppressant.  The second treatment was 
considered in patients who initially received GC alone.  Factors influencing decision to treat were 
analyzed using logistic regression, and those influencing choice of treatment by multinomial logit.     
Results 
Serum albumin and proteinuria were significantly different between those treated  (66.3%) and those 
not treated (33.7%).  Patients with a serum albumin of <2.5 mg/dL were more likely to be treated (OR 
1.88, p=0.007, 95% CI [1.19,2.98]), as were those with greater 24 hour proteinuria (OR 1.12 for each 
1g/day increase,p=<0.001, 95% CI [1.06,1.18]).  Patients in the TGNR were less likely to be treated than 
those in the GDCN (OR 0.45, p=0.001, 95% CI [0.28,0.72]).  Of the factors analyzed with regards to choice 
of treatment, only sex was significant.  Females were 3.49 times more likely to receive a calcineurin 
inhibitor than an alkylating agent (p=0.011, 95% CI [1.33,9.20]).  Changes in choice of first therapy were 
observed over time.  GC alone was the predominant approach until about 1994, at which time alkylating 
agents became the predominant choice. CNI were used in a minority of patients.    
Discussion 
Serum albumin, proteinuria, and registry were the only independent determinants of the decision to 
treat with immunomodulators.  Sex was the only factor associated with the specific choice of therapy 
between alkylating agents and CNI; however, the sample size of those treated may have been too small 
to detect differences.   
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Factors Influencing Choice of Treatment in Idiopathic Membranous 
Nephropathy 
 
Introduction 
Idiopathic membranous nephropathy (IMN) is the most common cause of nephrotic syndrome in adults.  
The course of the disease is variable, with approximately equal numbers of patients experiencing 
spontaneous remission, having persistent proteinuria but stable renal function, or progressing to end-
stage renal disease (ESRD).  A recent study found that 32% of patients receiving only conservative 
therapy (no immunosuppression) achieved spontaneous remission over a mean follow-up time of 6.2 
years.1  Though some prognostic factors have been identified that can help predict the likelihood of 
progression and stratify risk1,2 - thus identifying some patients as low-risk and not likely to benefit from 
treatment- there are still a number of patients at moderate to high risk of progressive disease.  
Immunomodulatory treatment can significantly decrease the rate of progression to ESRD,3-6  and those 
at increased risk for progression may derive substantial benefit from immunomodulatory therapy.  
However, the potential adverse effects associated with immunomodulatory treatment are significant, 
and thus the decision of whether to treat an individual patient and with what regimen is an important 
one.   
 
Initially, glucocorticoids (steroids) were commonly used for treatment of IMN, but more recent data has 
suggested that they are not effective when used alone.  In 1989, Cattran et al. conducted an RCT 
comparing a 6 month course of prednisone to conservative treatment; after a mean follow-up of 48 
months, they found no significant difference in change in creatinine clearance, remission rate, or 
progression to renal survival.7  In 1990, Healy et al. conducted another relatively large RCT comparing a 
short course of high-dose prednisone to controls and found that after 3 years, there was no significant 
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difference between groups in creatinine clearance or proteinuria.8  Thus, other agents have replaced 
steroids as first line treatment for IMN.   
 
The combination of an alkylating agent (cyclophosphamide or chlorambucil) and glucocorticoids given 
alternately for 6 months has been shown to be effective in increasing the remission rate and renal 
survival in patients with IMN.  Also known as the Ponticelli protocol, this regimen is commonly used as 
first line choice for patients with IMN receiving immunosuppressive therapy.  Two randomized 
controlled trials demonstrated the efficacy of a 6-month regimen alternating an alkylating agent and 
steroids.3,4  The first, by Ponticelli et al. in 1995, found that after 10 years patients who received the 
immunosuppressive treatment had significantly lower rates of ESRD (60% with chlorambucil/steroids vs. 
92% for conservative treatment).3  The second study also followed patients for 10 years and found a 
similar reduction in the proportion who progressed to ESRD: 65% of those taking 
cyclophosphamide/steroids vs. 89% of those receiving conservative treatment.4  In 1998, another 
randomized trial by Ponticelli et al. demonstrated that cyclophosphamide plus steroids had equivalent 
efficacy to chlorambucil plus steroids.9  
 
Cyclosporine (a calcineurin inhibitor) is another immunosuppressive drug that has been used to treat 
IMN; several studies point toward its efficacy in treatment of IMN.5,6  Cattran et al. in 1995 randomized 
patients with progressive disease to cyclosporine or placebo.  They found that treatment slowed the 
decline in renal function and decreased proteinuria in these patients.5  In 2001, Cattran at al. 
randomized patients with normal renal function to cyclosporine plus steroids or steroids alone.  Patients 
in the cyclosporine group had lower levels of proteinuria and a greater rate of remission (compared with 
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the steroids-only group), though there was no difference in renal function between the two groups.6  
However, these studies lack long-term follow-up and did not compare renal survival.     
 
 Although both are commonly used as immunomodulatory treatment for IMN, there is little high quality 
evidence to guide the choice between cyclophosphamide- and cyclosporine-based regimens.  A single 
head-to-head RCT comparing the two was done by Chen et al. in 2010.10  They found no significant 
difference in remission rates or change in eGFR between groups; however, their follow-up period was 
relatively short (1 year), and quality of the study was poor.  Thus, the question remains unresolved and 
more studies will need to be done before it can be answered.   
 
The choice of treatment depends upon a number of factors, yet which of these factors predicts the 
decision to treat or the choice of treatment is unknown and likely varies significantly between clinicians.  
Further, the relative efficacy of each treatment is unknown; though both provide a significant potential 
benefit, they also have substantial side effects and adverse events associated with their use.  Comparing 
outcomes retrospectively between patients receiving different treatments would be valuable.  
Importantly, this would be the only feasible way to compare long term outcomes, such as renal survival 
and mortality, not just short term rates of remission (as is usually studied in prospective comparisons).  
However, because the risks associated with each treatment regimen are different, it is most plausible 
that the choice of therapy is not random.  Therefore, understanding which factors predict choice of 
treatment is necessary if an unbiased comparison of these agents is to be conducted.  The purpose of 
this current study is therefore to identify what factors are associated with the decision to treat and with 
choice of treatment.   
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Methods 
We conducted a retrospective analysis of a pooled cohort of patients with IMN drawn from two large 
glomerular disease registries: GDCN and TGNR.  Patients were assigned to one of four groups based on 
initial treatment: no treatment, alkylating agents (cyclophosphamide or chlorambucil), calcineurin 
inhibitors (cyclosporine or tacrolimus), or steroids alone.  A number of patient factors thought to be 
related to the decision to treat and/or choice of treatment were identified a priori and analyzed using 
logistic regression techniques.  We first analyzed the decision of whether to treat with an 
immunomodulatory agent (treated vs. untreated).  Next, among patients who were treated, we 
determined the likelihood of receiving each agent based on various patient factors using multinomial 
logistic regression (Figure 1).  We felt that the 2-step analysis was appropriate for two reasons.  First, 
this is the logical sequence of decision-making in a clinical setting.  Second, the factors influencing the 
decision of whether to treat may be different than those influencing the choice of treatment.  We 
suspect the decision to treat depends upon prognostic factors, whereas the choice of treatment might 
be related more to side effect profile (e.g. sex, comorbidities, BMI).  All patients enrolled in their 
respective registries did so with IRB approved informed consent.   The current analysis study was 
approved by the University of North Carolina institutional review board.   
 
Study population 
The cohort (N=720) was comprised of patients from the Glomerular Disease Colloborative Network 
(GDCN, n=328) enrolled between 1969 and 2010 and from the Toronto Glomerulonephritis Registry 
(TGNR, n=392) enrolled between 1974 and 2010.  Records were collected for patients in the registries 
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from time of initial biopsy diagnosis or from time of clinical presentation.  Inclusion criteria were age >16 
years old, biopsy-proven IMN, and follow up after biopsy.  Patients were excluded if they had evidence 
of a secondary cause of membranous nephropathy (MN), including hepatitis B, hepatitis C, human 
immunodeficiency virus (HIV), syphilis, lupus (SLE), or if they had other autoimmune disease requiring 
immunosuppression.   
Of an original 470 patients with MN identified from the GDCN and 520 from the TGNR, 118 were 
excluded for secondary causes or incomplete data, 130 for inadequate follow-up, 8 for inadequate 
biopsy, and 14 for age <16 years old (see Figure 2).  This yielded a final cohort of 720 subjects.   
 
Variables 
All registry data to be reviewed and analyzed were specified prior to collection.  A comprehensive list of 
variables thought to influence treatment choice was considered; these included age, sex, body mass 
index (BMI), estimated glomerular filtration rate (eGFR), blood pressure, time from biopsy to treatment 
initiation, pathologic stage, degree of interstitial fibrosis, baseline proteinuria, baseline serum albumin, 
insurance status, race, and education level.  The presence of hypertension, diabetes, hyperlipidemia, as 
well as any history of cardiovascular disease, malignancy, venous thromboembolism (VTE) or pulmonary 
embolus (PE), or psychiatric disease were also considered.  Site (GDCN or TGNR) was analyzed to 
determine whether there were systematic differences in choice of treatment.  Factors were chosen if 
they were known or suspected to influence the clinical decision to treat with an immunomodulatory 
agent and/or the choice of which type of agent to use.  Variables of interest included those that predict 
prognosis, as well as patient factors that might influence the choice of one agent over another, 
particularly as they related to the side effect profiles of the different agents.  For example, fertility (age 
and sex) is of concern when using cyclophosphamide, BMI and insulin resistance are important 
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considerations when using steroids, and low GFR or hypertension are relevant when choosing to use a 
calcineurin inhibitor.   
 
Variables were later excluded if no data was available in the registry, if there was a large proportion of 
missing data (see Table 1), or if there was an insignificant relationship with outcome of interest.  The 
final analysis of decision to treat included the covariates site, sex, age, race, serum albumin, 24-hour 
proteinuria, eGFR, and mean arterial pressure (MAP); the analysis of choice of treatment included site, 
sex, age, serum albumin, eGFR, and MAP.  When including eGFR in the model, we tried analyzing it in 
two different ways- as a continuous variable and as a categorical variable, grouped into clinically 
meaningful ranges.  The latter corresponded to levels at which decision making was predicted/expected 
to change - i.e. very low such that there might be a relative contraindication for calcineurin inhibitors or 
that treatment might be considered futile, intermediate such that the patient would be more likely to 
merit and benefit from treatment, and higher where the patient has a better prognosis and is less likely 
to be treated (since they are more likely have a benign course even if untreated).   
 
Statistical analysis 
We first compared all patients receiving immunomodulatory treatment (alkylating agent, calcineurin 
inhibitor, steroids, or other immunomodulators) to those receiving no immunomodulatory treatment  
(Figure 1).  Group determination was made by initial immunosuppressive agent or regimen used.  The 
second treatment was considered in patients who initially received steroids alone.  The reason for doing 
this was that steroids are often given first either empirically before a definitive diagnosis is made (prior 
to biopsy), or possibly without recognition or awareness that this is no longer a recommended option 
for this disease.  Our objective in this study was to compare calcineurin inhibitors to alkylating agents, 
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and felt that this method of classification would more appropriately categorize patients like this.  
Patients were included in a treatment group if treatment was initiated, regardless of whether it was 
discontinued early and regardless of outcome, as our objective was to analyze the variables affecting 
choice to treat.  Logistic regression was used to calculate odds ratios for the likelihood of receiving 
treatment for each of the patient factors listed above.   
 
The second step of the analysis investigated choice of treatment among those patients who received 
immunosuppressive therapy.  The three treatment groups were alkylating agents (chlorambucil and 
cyclophosphamide), calcineurin inhibitors (cyclosporine and tacrolimus), and steroids only.  Patients 
were included in the alkylating agent or calcineurin inhibitor group if they received either type of drug, 
regardless of concomitant steroids use.  For patients who initially received steroids alone, the second 
treatment was considered.  Patients receiving other immunosuppressant therapy (azathioprine, 
rituximab, mycophenolate mofetil, or methotrexate) were excluded from this analysis.  Although some 
of these treatments have begun to be used more frequently (e.g. rituximab, mycophenolate mofetil), 
they remain relatively new and have not been well-studied yet; we had few subjects who received these 
medications as first-line therapy (n= 41).  As in the first step of the analysis, group allocation was made if 
treatment was initiated, regardless of duration.  We used multinomial logistic regression to model the 
relationship between the previously-specified patient factors and choice of immunosuppressive agent.   
 
Results were expressed as adjusted odds ratios with 95% CIs, and were considered significant if 
associated with a p-value of 0.05 or less.  All analyses were performed with STATA version 11 (StataCorp, 
College Station, Texas).   
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Results 
Characteristics of Sample 
The cohort was comprised of 720 adults with biopsy-proven membranous nephropathy, drawn from 2 
glomerular disease registries.  Approximately 62% of subjects were male and 78% were white, with a 
mean age at biopsy of 49.1 years (Table 2).  The mean eGFR at biopsy was 75.8 mL/min, mean serum 
albumin was 2.6 mg/dL, and mean 24-hour proteinuria was 8.1 g/day.   
 
Factors Associated with Decision to Treat 
The logistic regression model compared the 477 patients (66.3%) who received treatment to the 243 
who did not (33.7%).  Serum albumin, 24 hour proteinuria, and site (registry) were found to be 
significantly different between treated and untreated patients (Table 3).  Patients with a serum albumin 
of <2.5 mg/dL had 1.88 times the odds of being treated than those with a serum albumin >2.5mg/dL 
(p=0.007, 95% CI [1.19,2.98]).  For each 1 g/day increase in 24 hour proteinuria, patients had 1.12 times 
the odds of being treated (p=<0.001, 95% CI [1.06,1.18]).   
 
Patients in the TGNR were 0.45 times as likely to be treated as those in the GDCN (p=0.001, 95% CI 
[0.28,0.72]).  Approximately 77% of GDCN subjects received some type of immunomodulatory 
treatment, compared to 57% of TGNR subjects (Table 4).  This difference can be accounted for by the 
difference in number of patients receiving steroids alone: 56.7% of GDCN patients compared with 36.5% 
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of TGNR patients.  The proportion of patients receiving alkylating agents, calcineurin inhibitors, and 
other immunosuppressants was comparable between sites (Table 4).   
 
Time from biopsy to treatment initiation was calculated for treated patients.  Among treated patients, 
56.3% received treatment within 1 month, 68.9% within 3 months, 77.1% within 6 months, and 84.0% 
within 1 year.   
 
Factors Associated with Choice of Treatment 
The multinomial logit model compared patients receiving alkylating agents, calcineurin inhibitors, and 
steroids.  Patients receiving other immunomodulators (mycophenolate mofetil, azathioprine, rituximab, 
or methotrexate) were included in the analysis of decision to treat but excluded from this comparison as 
the group was small and comprised of patients taking different types of agents.  Of the 477 patients who 
were treated with immunomodulators, 159 (33.3%) received alkylating agents, 41 (8.6%) received 
calcineurin inhibitors, and 255 (53.5%) received steroids only (Table 3).  For the comparison of factors 
affecting choice of treatment, we only included patients who were treated in 1983 or later, as this was 
when use of alkylating agents and calcineurin inhibitors began (Figure 3).   
 
Gender was the only factor found to be significant in determining choice of treatment.  Females were 
3.49 times more likely to receive a calcineurin inhibitor than an alkylating agent (p=0.011, 95% CI 
[1.33,9.20]), and 0.38 times as likely to receive an alkylating agent compared to steroids alone (p=0.001, 
95% CI [0.21,0.69]).  The results of the multinomial logit analysis of choice of treatment are summarized 
in Table 5.     
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We also compared the choice of treatment by year to assess what trends existed in the use of different 
agents over time (Figure 3).  Years of treatment initiation for this cohort ranged from 1963 to 2006. Prior 
to 1983 there was no use of calcineurin inhibitors and almost no use of alkylating agents; treatment was 
almost entirely with steroids alone.  Use of calcineurin inhibitors and alkylating agents increased 
beginning in 1983, and by 1994 alkylating agents surpassed steroids alone as the predominant choice of 
treatment.   
 
Discussion 
There are a variety of factors that clinicians consider when deciding whether to use immunomodulatory 
treatment for a patient with IMN and if so, what type of regimen should be used.  Though existing 
studies and recommendations describe prognostic factors and guidelines on who should be treated,1,2,11 
the decision is not clear-cut in many instances, and often depends on numerous patient factors and 
clinical data.  We analyzed a cohort of patients with IMN drawn from 2 glomerular disease registries to 
determine which factors were associated with an increased likelihood of being treated.  The goal of this 
analysis was to determine whether there were differences between patients receiving different types of 
treatment (specifically, alkylating agents and calcineurin inhibitors) and if so, what they were.  This is 
necessary before outcomes can be compared between the two groups.  A retrospective comparison like 
this would provide valuable information on long-term efficacy and outcomes, but selection bias must be 
assessed first.   
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Serum albumin level, proteinuria, and site were independent predictors of the decision to treat with 
immunomodulators; an albumin level of <2.5 mg/dL, higher 24 hour proteinuria levels, and being in the 
GDCN (vs. TGNR) were associated with an increased likelihood of being treated.  The association of 
albumin and proteinuria with decision to treat is consistent with current evidence and 
recommendations, as these correlate with prognosis and likelihood of progression, and the decision to 
treat is based largely upon expected risk of progression.   
 
The reason for the significant difference in likelihood of treatment between sites is not clear.  However, 
the difference in treatment rates between sites is accounted for by a substantial difference in the use of 
steroids; both sites had similar rates of use of alkylating agents, calcineurin inhibitors, and other 
immunosuppressants.  One potential explanation for the difference in rates of treatment is a difference 
in composition of the two registries, in terms of proportion of clinicians or subjects in an academic 
setting versus a private practice setting, and the relationship of the individual nephrologists and the 
university program.  We did not pursue this question here, but it remains an interesting issue for future 
investigation.  Sex, age at biopsy, race, eGFR, and blood pressure were not found have a significant 
independent association with the decision to treat.   
 
For patients receiving treatment, we also analyzed factors thought to influence the choice of therapy- 
alkylating agent-based, calcineurin inhibitor-based, or steroids alone.  In this analysis, females were 
significantly less likely to receive an alkylating agent as compared to a calcineurin inhibitor or steroids 
alone.  This makes sense clinically, as alkylating agents are generally avoided in women of childbearing 
potential.  Site, age, albumin level, proteinuria, eGFR, and blood pressure were not found to be 
independent predictors of one treatment over another.  Some of these were surprising, as we expected 
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there to be differences in more factors between groups (e.g. eGFR and BP relevant to choice to use 
calcineurin inhibitor, as described earlier).  However, our sample size was likely too small to detect 
significant differences that may exist.  Though the cohort was quite large, the number of patients who 
received alkylating agents and especially calcineurin inhibitors was surprisingly small.  The limited 
numbers in these groups, as well as missing data, decreased the number of observations in the 
multinomial logit model and thus its power to detect differences.   
 
In addition to identifying the factors predictive of treatment decision, we also characterized some of the 
temporal patterns of treatment in this cohort.  Specifically, we looked at the choice of treatment over 
time (by year of treatment) as well as the time from biopsy to treatment.  The trends in choice of 
treatment during the observation period were interesting.  Use of alkylating agents and calcineurin 
inhibitors did not emerge until 1983; prior to this almost all immunomodulatory treatment was with 
steroids alone.   We expected to find these different ‘eras’ of treatment, given that calcineurin inhibitors 
were not available earlier and data supporting the use of alkylating agents did not begin to accumulate 
until the 1980s.  Use of alkylating agents increased over time, and in 1994 they became the most 
common choice of treatment, surpassing steroids alone.  However, the choice of steroids alone as a first 
line agent continued to be common, which was surprising, given the available evidence that this is not 
an effective treatment option for IMN.7,8   
 
The distribution of time from biopsy to treatment was also surprising.  The majority of patients who 
received immunomodulatory treatment were treated within the first few months of biopsy.  For 
patients diagnosed with IMN, the literature suggests in most cases that patients be followed for about 6-
12 months after biopsy or presentation before deciding whether to treat.  This allows the clinician to 
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understand the clinical course and obtain more prognostic information, which is important, as the 
natural history of IMN can vary, from stable and benign in some to progression to ESRD in others.  
Though numerous prognostic factors have been identified, many of these are not very strong predictors 
of progression, and often are unable to predict patients’ course or progression with much certainty.  It 
was surprising to find that most patients received treatment early in their course, rather than after an 
observation period to better assess their course and risk of progression.  The reasons for early treatment 
in a majority of patients are unclear, but the finding highlights a discrepancy between perceived or 
recommended practice and actual practice which would be worth pursuing.   
 
Our combined cohort, the product of a collaboration that utilized 2 major glomerular disease registries, 
provided a sample far larger than prior studies of MN have been able to achieve, yet was still limited in 
its power to identify and analyze differences between treatment groups.  In order to begin investigating 
and answering some of the important questions about treatment of this disease, such as the 
comparative effectiveness of different treatment choices, more data and even greater collaboration will 
be needed.   Though the design of retrospective studies is limited and on their own are generally not 
adequate to answer clinical questions with certainty, they are a very important part of clinical outcomes 
research.  Good quality retrospective analyses can identify important issues for further investigation and 
can prompt further prospective research, and are therefore a necessary first step in pursuing better 
clinical information and evidence to guide decision-making.     
 
The results of this study address an important question that must be answered before a retrospective 
comparison of outcomes can be undertaken.  Specifically, whether there are significant differences 
between patients receiving different treatments (alkylating agents versus calcineurin inhibitors), what 
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those differences are, and how they affect the choice of treatment.  As there is good reason to believe 
that patients receiving different treatments may differ in meaningful ways from each other, they cannot 
be compared without controlling for these factors.  Thus, we sought to understand and quantify any 
selection bias present between these groups.  Having identified the factors associated with choice of 
treatment, these can be controlled for in a comparison of outcomes between groups.  It is important to 
note that there may be factors that differ between groups and would contribute to potential selection 
bias, but which did not achieve statistical significance in this analysis (due to small sample size.  To 
address this, other factors thought to be meaningful could also be controlled for, or other statistical 
methods could be used to account for these differences, such as propensity scores.  Though there are 
limitations, this analysis provides important and relevant information and makes an outcomes analysis 
between these groups feasible.   
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Table 1.  Number of subjects with missing values for covariates considered 
Variable 
Number of subjects 
with missing data 
(%) 
Sex 0 (0) 
Age at biopsy 0 (0) 
BMI 356 (49.4) 
Serum albumin 112 (15.6) 
24 hr proteinuria 83 (11.5) 
eGFR 74 (10.3) 
MAP 71 (9.9) 
Smoking status 282 (39.2) 
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Table 2.  Cohort Characteristics 
  Combined 
Cohort 
(n=720) 
GDCN 
(n=328) 
TGNR 
(n=392) 
Gender       
   Female 272 (37.8%) 138 134 
   Male 448 (62.2%) 190 258 
Mean age at biopsy (SD) 49.1 (15.6) 51.0 (15.3) 47.5 (15.6) 
Race       
   White 490 (77.5%) 219 271 
   Black 80 (12.7%) 61 19 
   Other 62 (9.8%) 6 56 
Smoking       
   Never 162 (37.0%) 56 106 
   Ex 131 (29.9%) 43 88 
   Current 145 (33.1%) 52 93 
Mean BMI at biopsy (SD) 27.3 (5.5) 29.7 (6.9) 26.8 (5.0) 
Mean serum albumin at 
biopsy (SD), mg/dL 
2.6 (0.7) 2.5 (0.8) 2.7 (0.7) 
Mean 24 hour 
proteinuria at biopsy 
(SD), g/day  
8.1 (7.2) 9.3 (9.0) 7.0 (4.5) 
Mean eGFR at biopsy 
(SD), mL/min 
75.8 (34.4) 78.4 (37.6) 73.6 (31.3) 
Blood pressure (MAP) 102.2 (14.0) 102.4 (14.6) 102.1 (13.5) 
 
Values given as n (%) for categorical data and mean (SD) for continuous data.  BMI=body mass index, 
eGFR=estimated glomerular filtration rate, MAP=mean arterial pressure, GDCN=Glomerular Disease 
Collaborative Network, TGNR=Toronto Glomerulonephritis Registry.   
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Table 3.  Factors influencing decision to treat.   
  Adjusted 
Odds 
Ratio 
P-value 95% CI 
Site/registry       
   GDCN 1     
   TGN 0.45 0.001 [0.28,0.72] 
Gender       
   Male 1     
   Female 0.73 0.18 [0.46,1.16] 
Age at biopsy 0.99 0.11 [0.97,1.00] 
Race       
   White   1     
   Other 0.86 0.57 [0.51,1.46] 
Serum albumin <2.5 
mg/dL 
1.88 0.007 [1.19,2.98] 
24 hour proteinuria 
(g/day) 
1.12 <0.001 [1.06,1.18] 
eGFR (per 10 mL/min) 0.97 0.45 [0.89,1.05] 
Blood pressure (MAP) 1 0.72 [0.98,1.01] 
 
GDCN=Glomerular Disease Collaborative Network, TGNR=Toronto Glomerulonephritis Registry, 
eGFR=estimated glomerular filtration rate, MAP=mean arterial pressure.   
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Table 4.  Distribution of different treatments among cohort.    
  Combined 
Cohort  
GDCN TGN 
n=720 n=328 n=392 
Treated 477 (66.3%) 253 (77.1%) 224 (57.1%) 
Alkylating agent 106 (14.7%) 50 (15.2%) 56 (14.3%) 
   With steroids 76 45 31 
   Without steroids 30 5 25 
Calcineurin inhibitor 30 (4.2%) 11 (3.4%) 19 (4.8%) 
   With steroids 8 5 3 
   Without steroids 22 6 16 
Other immunosuppressant 12 (1.7%) 5 (1.5%) 7 (1.8%) 
   With steroids 8 2 6 
   Without steroids 4 3 1 
Steroids only 329 (45.7%) 186 (56.7%) 143 (36.5%) 
   2nd treatment- alkylating agent 53 31 22 
   2nd treatment- calcineurin inhibitor 11 3 8 
   2nd treatment- other immunosuppressant 8 5 3 
   No other treatment 255 147 110 
 
Values given as n (%).   
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Table 5.  Factors influencing choice of treatment.   
 
  
Alkylating agent vs. 
Steroids only 
Calcineurin inhibitor 
vs. Steroids only 
Calcineurin inhibitor 
vs. Alkylating agent 
  RRR 
p-
value 95% CI RRR 
p-
value 95% CI RRR 
p-
value 95% CI 
site= TGNR 0.51 0.359 [0.123,2.14] 0.235 0.262 [0.019,2.94] 0.46 0.561 [0.034,6.31] 
sex= female 0.38 0.001 [0.207,0.685] 1.32 0.551 [0.534,3.24] 3.49 0.011 [1.33,9.20] 
age at biopsy 1.01 0.416 [0.988,1.03] 0.991 0.606 [0.959,1.02] 0.983 0.329 [0.949,1.02] 
albumin 0.78 0.282 [0.500,1.22] 0.487 0.147 [0.184,1.29] 0.622 0.358 [0.226,1.71] 
24 hr proteinuria 1.05 0.284 [0.960,1.15] 1.13 0.039 [1.01,1.27] 1.08 0.193 [0.963,1.21] 
eGFR, per 10 mL/min 0.98 0.608 [0.898,1.07] 0.985 0.852 [0.843,1.15] 1.01 0.926 [0.859,1.18] 
MAP 1.01 0.222 [0.993,1.03] 0.984 0.382 [0.950,1.02] 0.973 0.14 [0.939,1.01] 
 
TGNR=Toronto Glomerulonephritis Registry, eGFR=estimated glomerular filtration rate, MAP=mean 
arterial pressure.   
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Adult patients with IMN
Treated
(with immunosuppression)
Untreated 
(no immunosuppression)
Alkylating agent-
based regimen 
(cyclophosphamide or 
chlorambucil)
Calcineurin inhibitor-
based regimen
(cyclosporine or tacrolimus)
Steroids alone
Figure 1.  Treatment group allocation and approach to analysis.  
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GDCN TGN
470 patients 
with MN
520 patients 
with MN
Excluded:
Final cohort: 
328 patients
Final cohort: 
392 patients
Secondary causes
Inadequate followup
Inadequate biopsy
<16 years old
Combined cohort: 
720 patients
95
33
8
6
23
97
0
8
Figure 2.  Cohort derivation.  
Total of 142 
excluded
Total of 128 
excluded
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Figure 3.  Choice of treatment over time.   
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Systematic Review 
 
Introduction 
Idiopathic membranous nephropathy (IMN) is the most common cause of nephrotic syndrome in adults.  
The course of the disease is variable, with approximately equal numbers of patients experiencing 
spontaneous remission, having persistent proteinuria but stable renal function, or progressing to end-
stage renal disease (ESRD).  Untreated, some patients will do well, whereas a significant number will 
progress to ESRD.  Some prognostic factors can help predict the likelihood of progression and stratify 
risk- thus identifying some low-risk patients who are not likely to benefit from treatment- a significant 
number are at moderate to high risk of progressive disease.  In these patients, there is a significant 
potential to benefit from treatment, but this must be weighed against the risks of treatment.   
 
Alkylating agents and calcineurin inhibitors are both accepted options for first-line treatment of IMN.  
Unfortunately, these treatment options have a number of associated side effects and risks.  Examples of 
important risks include potential infertility in women with cyclophosphamide, increased risk of 
malignancy with long-term use of cyclophosphamide, risk of renal failure with calcineurin inhibitors, and 
risks of weight gain, glucose intolerance or diabetes, among many others, with glucocorticoid (steroid) 
use.   
 
These agents can be used alone or in combination with steroids.  Steroids are sometimes used alone for 
treatment; however, evidence has demonstrated that this is not an effective treatment option.1,2  Thus 
this review will not address steroid treatment of IMN, but rather address treatments that are less well 
tested and understood.  Given the variable course of IMN as well as the risks and potential benefits 
associated with immunomodulatory treatment, it is important to understand the evidence supporting 
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the efficacy of these agents.  Further, it would be valuable to determine what is known about the 
comparative effectiveness of these two agents and what work remains to be done in this area.   
 
The purpose of this systematic review was to synthesize and describe the existing evidence regarding 
the effectiveness of calcineurin inhibitors and alkylating agents for the treatment of IMN, and to 
determine whether one is more effective than the other for initial treatment.     
 
Methods 
Data sources and Searches 
The search strategy included a search of MEDLINE.  PubMed was searched using the MeSH terms 
(“membranous glomerulonephritis”) AND *(“cyclosporine” or “tacrolimus) OR (“cyclophosphamide” OR 
“chlorambucil”)+, with results limited to those in English, as well as those in humans and adults (ages 
19+), published in any year.  Related articles and bibliographies of relevant articles were also reviewed.   
 
Study Selection 
A single author (SM) performed the above searches as well as the study selection. This review sought to 
include studies that addressed the efficacy of immunomodulatory treatment with either an alkylating 
agent or a calcineurin inhibitor as an intervention in adults with IMN.  Study designs to be included were 
randomized controlled trials (RCTs), prospective and retrospective cohort studies, and case control 
studies.  Case reports and case series would be excluded, as would studies without a control or 
comparison group.  Comparison groups include any of the following: a control group receiving 
conservative treatment (i.e. no immunosuppression), placebo or no treatment group, or a group 
receiving the other agent of interest (e.g. if the intervention was a calcineurin inhibitor, the comparison 
might be an alkylating agent).  The outcome of interest is efficacy or effectiveness of the treatment; this 
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could be measured or defined in several ways: mortality, renal survival (or time to ESRD/renal 
replacement/transplant), remission rate (partial and complete), and renal function (eGFR).  Other 
inclusion criteria are that articles be available through the University of North Carolina Health Sciences 
Library and be in English.   
 
Data Extraction and Quality Assessment 
Articles were reviewed and their methodology appraised using predetermined quality criteria.  To 
evaluate the methodologic rigor and quality of the studies a single author (SM) assessed the potential 
for selection bias, measurement bias, magnitude of effect, and overall internal validity.  External validity, 
or generalizability, was also evaluated.  Articles were assigned an overall grade based on design and 
quality.  The grade was based on the overall assessment of the internal validity of the study, taking into 
account potential bias and how significantly it might affect the results found in the study.  Data to be 
compared between studies was extracted and summarized in a table (Table 1).   
 
Results 
Search Results 
The initial MeSH search in PubMed returned 140 results- the titles were reviewed first to determine 
relevance to the study question and selection criteria; if studies could not be confidently excluded based 
on title, the abstract was reviewed.  Of the 140 search results, 108 citations were excluded based on the 
title and/or abstract.  Of those remaining, 14 could not be retrieved and four were not in English, leaving 
14 articles to undergo full-text review (Figure). Of these, four of the full-text articles were excluded: two 
for wrong population, one for wrong intervention, and one for wrong control/comparison group.  
Ultimately, 10 studies were included in the review. 
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Study Characteristics 
Table 1 summarizes the characteristics of included studies.  There were six RCTs,3-8 two prospective 
cohort studies,9,10 one non-randomized controlled trial,11 and one retrospective cohort study.12  The 
sample size of included studies ranged from 17 to 93 subjects.  The study population in all cases included 
patients with IMN, and most studies required that subjects also have nephrotic range proteinuria.  Three 
were directed at patients with progressive disease or renal insufficiency.   
 
Study Quality 
Table 2 summarizes the appraisal and grading of the studies.   
 
Three studies received a grade of ‘good,’ three were ‘fair,’ and four studies were ‘poor.’  The major 
limitation to quality was selection bias, as well as some measurement bias.  Problems with selection bias 
included significant levels of dropout or loss to follow-up and baseline differences between groups.  
External validity was generally good- most of the RCTs were not too limiting in their exclusion criteria- 
but many of the studies were limited by short follow-up time, as well as use of intermediate outcomes.   
 
Findings 
Alkylating agents vs. calcineurin inhibitors 
Only one study directly compared alkylating agents to calcineurin inhibitors.3  This study found no 
difference in remission rates at one year between patients treated with one agent or the other.  
However, this study was of poor quality overall and had a relatively short followup of one year.  
Additionally, the study was conducted in China, which may limit the generalizability of the findings when 
considering North American or Western populations.  Thus, there is currently no good quality evidence 
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available to address the question of whether alkylating agents or calcineurin inhibitors are more 
effective in treating IMN.   
 
Alkylating agents vs. control 
Five studies compared the efficacy of alkylating agent-based regimens to control- conservative 
treatment or steroids.6-8,10,12  There were three RCTs,8-10 one prospective cohort study,10 and one 
retrospective cohort study.12  Four of the five studies found that treatment with an alkylating agent 
improved outcomes, though primary outcomes and endpoints varied between studies.6,7,10,12  The 1992 
study by Falk et al. failed to find a difference in renal survival between patients treated with 
cyclophosphamide + steroids and those treated with steroids alone.8  This study was relatively small 
(n=26) and of fair quality.  Taken together, the bulk of the evidence regarding alkylating agent-based 
regimens supports an improvement in outcomes with their use.  The most convincing evidence comes 
from the two large RCTs- by Jha et al. in 2007 and Ponticelli et al. in 1995- both of which have 10 years 
of follow-up.6,7 
 
Ponticelli et al. evaluated a 6-month regimen of alternating chlorambucil and steroids that became 
known as the Ponticelli protocol; this was compared with conservative treatment in a group of 81 
subjects from Italy.7  This study found that at 10 years, the proportion of subjects reaching ESRD was 
significantly smaller in the treated group than in the control group.  Strengths of this study include the 
long duration of follow-up (compared with other studies) as well as their choice of ESRD as an endpoint, 
which provides more meaningful evidence than intermediate outcomes (such as renal function and 
remission rate) alone.  The internal validity of this study is limited somewhat by the number of patients 
lost to follow-up, though the magnitude of the effect found was fairly large and the potential selection 
bias would likely not be able to account for the differences found.   
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A later study by the same group demonstrated that using cyclophosphamide in place of chlorambucil 
was equally efficacious but resulted in fewer side effects;13 chlorambucil is no longer used in alkylating 
agent-based regimens.   
 
In 2007, Jha et al. published the results of a similar RCT comparing cyclophosphamide and steroids to 
conservative therapy.6  Their study was slightly larger (n=93), and also followed patients for 10 years.  
They compared the percentage of patients achieving remission, the percentage with ESRD-free survival, 
and the percentage not reaching any endpoints (death, ESRD, or doubling of serum creatinine) at 10 
years, and found significant differences between experimental and control groups for each.  This study 
had some loss to followup, though not as much as in the Ponticelli study7 described above.  Further, 
there was some crossover from control to treatment (control subjects had the option to be treated with 
an alkylating agent 24 months or more after randomization if they wished).  With an intention-to-treat  
(ITT) analysis, such crossover would bias toward the null and underestimate the effect size.   
 
Torres et al. conducted a retrospective comparison of 2 historical cohorts.12  They compared the 
outcomes of patients with progressive IMN treated during 2 consecutive time periods at their hospital.  
During the first, patients did not receive any immunosuppressive treatment, and during the second, all 
patients with progressive disease received chlorambucil and steroids.  This study was limited by the 
potential selection bias and confounding inherent in the retrospective design, though the groups 
seemed similar at baseline with respect to a number of variables.  This study found large differences 
between groups in change in creatinine clearance over time as well as percentage with renal survival, 
though no difference was found in patient survival at any time.   
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In 1992, Jindal et al. published the findings of a small prospective cohort of patients (n=9) with IMN that 
had been treated with cyclophosphamide.10  They compared the cohort to a matched control (n=17) 
that had never been treated with cyclophosphamide, drawn from a glomerular disease registry in 
Toronto.  The controls were matched on five factors, and appeared similar for these variables, but there 
were a number of other potentially confounding factors that were not matched.  As with the above 
study by Torres et al.,12 this potential bias limits internal validity, though the longer follow-up and 
minimal exclusion criteria make this observational study a valuable complement to RCTs.   
 
Calcineurin inhibitors vs. control 
Four studies compared the efficacy of calcineurin inhibitor-based regimens to control- conservative 
treatment, placebo, or steroids.4,5,9,11  The quality of the studies varied, as did the endpoints measured, 
but the evidence pointed toward an overall benefit associated with use of calcineurin inhibitors.  The 
1995 study by Cattran et al. found that treatment of IMN with cyclosporine slowed the rate of decline in 
creatinine clearance significantly, as compared with a placebo group.11  This study was relatively small 
and the endpoint was an intermediate outcome, but demonstrated a clinically important effect and 
served as a starting point for other investigations of cyclosporine’s efficacy.  This study included only 
patients with worsening renal function (progressive disease).   
 
A later RCT by Cattran et al. in 2001 enrolled patients with IMN who had failed to achieve remission with 
at least 2 months of steroid treatment (steroid-resistant).5  This RCT was of good quality and found a 
significant difference in rates of remission at all measured time points (26, 52, and 78 weeks).  The 
outcome of interest was different (remission rate vs. change in creatinine clearance), and though still an 
intermediate outcome (as compared to renal survival or mortality), both studies demonstrated a benefit 
with cyclosporine treatment.   
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In 2007, Praga et al. conducted an RCT evaluating a different calcineurin inhibitor, tacrolimus, as 
treatment for IMN.4  Their study was of fair quality, limited by higher dropout rates and some baseline 
differences between tacrolimus and control groups.  The outcome of interest in this study was remission 
rate after treatment, at 12 and 18 months.  They also found a significant magnitude of effect, which 
would likely outweigh the effect of any selection bias.   
 
The 2001 study by Yao et al. found similar results, with significantly different rates of remission following 
treatment with cyclosporine (versus conservative treatment with captopril).9  However, the internal 
validity of their study wasn’t as good, and its applicability to North American populations may be 
limited.   
 
Discussion 
A number of studies have addressed the efficacy of calcineurin inhibitors and alkylating agents in 
treatment of IMN.  These range from small, uncontrolled observational studies (excluded from this 
review) to larger, controlled and/or randomized ones.  There is some good quality evidence 
demonstrating an association between each agent and intermediate outcomes or indicators of 
effectiveness.  The existing evidence for calcineurin inhibitors demonstrates their role in increasing the 
likelihood of remission (both partial and complete) as well as decreasing the rate of decline in renal 
function (as measured by creatinine clearance).  Both cyclosporine and tacrolimus have been evaluated 
in prospective trials and appear to be effective.  The evidence for alkylating agents is somewhat 
stronger, as there have been larger studies with a longer duration of follow-up.  A number of these have 
used renal survival (survival free of end-stage renal disease, or ESRD) as an endpoint, which is a more 
patient-oriented and clinically significant outcome.  Several studies, of varying quality and size, have 
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found significant differences in renal survival between patients treated with alkylating agents and 
controls.  To date, just one study has addressed the comparative effectiveness of alkylating agents and 
calcineurin inhibitors.  Alone, it does not constitute good evidence for clinical decision-making or 
recommendations; more studies are needed to compare these agents head-to-head.   
 
The four studies comparing calcineurin inhibitors to a control all had similar findings that pointed toward 
the efficacy of calcineurin inhibitor-based regimens for treatment of IMN.  The consistency of these 
findings supports this hypothesis, and it is important to note that the results were found in different 
populations of patients with IMN- some with progressive disease, some steroid-resistant, and some with 
persistent (though not necessarily progressive) disease.  One important limitation of these studies is the 
relatively short follow-up.  The longest follow-up was in the prospective study by Yao et al.,9 but the 
RCTs were limited in the duration of their follow-up.  Also, these studies evaluated intermediate 
outcomes, such as creatinine clearance and remission rates (partial and complete), but did not measure 
more meaningful and patient-centered outcomes such as renal survival or mortality.  Doing so would 
likely require significantly greater followup time, which is difficult with an RCT.   
 
Implications for research 
This review summarizes the existing evidence regarding treatment of IMN with alkylating agents and 
calcineurin inhibitors as of early 2011.  A number of RCTs of varying quality have been performed, as 
well as some controlled observational studies, to assess this.  When taken together, the majority of 
these studies are consistent with each other in the direction of the effect found, and provide more 
reliable evidence of the efficacy of these agents as measured by the outcomes identified.  One limitation 
of the evidence is the lack of data on outcomes such as mortality, and for calcineurin inhibitors, on renal 
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survival.  This is partly due to the small number of good-quality studies with long-term follow-up, since 
these outcomes take longer to develop than remission or changes in renal function.   
 
The studies summarized above used varying doses of medications and durations of treatment, and 
consequently, there is not any clear evidence regarding the lowest effective dose or shortest effective 
duration of treatment.  Some studies have tested low-dose regimens (particularly of calcineurin 
inhibitors) in an attempt to address this, but further studies are needed.     
 
Finally, more research is needed to directly compare the effectiveness of calcineurin inhibitors and 
alkylating agents.  A large RCT with long-term follow-up would be expensive and time consuming, and is 
impractical, especially as a first step.  Efforts should be directed at designing good quality observational 
studies, which are an important complement to RCTs.  Observational studies are far more inclusive and 
generalizable, and so can help expand the more rigorous findings of RCTs to a broader patient 
population.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
37 
 
Figure.  Results of literature search and article selection.   
Titles and abstracts 
identified through searches:
n = 140
Citations excluded:
n = 108
Not in English:
n = 4
Unable to retrieve:
n = 14
Full-text articles retrieved: 
n = 14
Full-text articles excluded: 
n = 4
- 1 wrong intervention
- 1 wrong control/comparison group
- 2 wrong population
Articles included in this review:
n= 10
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Table 1 
 
  Study Study design Treatment studied Comparison/control # of subjects 
Calcineurin inhibitor vs. 
alkylating agent 
Chen et al. 2010 RCT Tacrolimus + steroid 
Cyclophosphamide + 
steroid 73 
Calcineurin inhibitor vs. 
conservative/placebo 
Praga et al. 2007 RCT Tacrolimus  Conservative 48 
Yao et al. 2001 
Prospective cohort 
with control Cyclosporine 
Conservative 
(Captopril)  30 
Cattran et al. 
2001 RCT Cyclosporine + steroid Steroid 51 
Cattran et al. 
1995 
Controlled trial (non-
randomized) Cyclosporine Placebo 17 
Alkylating agent vs. 
conservative/placebo 
Jha et al. 2007 RCT 
Cyclophosphamide + 
steroid Conservative 93 
Torres et al. 
2002 
Retrospective cohort 
(comparison of 2 
historical cohorts) Chlorambucil + steroid Conservative 39 
Ponticelli et al. 
1995 RCT Chlorambucil + steroid Conservative 81 
Falk et al. 1992 RCT 
Cyclophosphamide + 
steroid Steroid 26 
Jindal et al. 1992 
Prospective cohort 
with control 
Cyclophosphamide +/- 
steroid Steroid (some) 26 
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Table 1, continued 
 
  Study Population characteristics Regimen/dose Followup duration 
Calcineurin inhibitor vs. 
alkylating agent 
Chen et al. 
2010 
IMN + nephrotic syndrome; 
Chinese, drawn from 6 centers 
Tacrolimus 0.1mg/kg/day adjusted to 
trough level of 5-10ng/mL for 6 months, 
then decreased to trough level of 2-5ng/mL 
for 3 months 12 months 
Calcineurin inhibitor vs. 
conservative/placebo 
Praga et al. 
2007 
IMN + nephrotic syndrome 
lasting >9 months; conducted 
from 13 centers in Spain 
Tacrolimus 0.05mg/kg/day divided BID, 
adjusted to trough level of 3-5ng/mL, 
increased to trough level of 5-8ng/mL if no 
remission at 2 months, continued for 12 
mos; then tapered for 6 months (months 
12-18) 18 months 
Yao et al. 
2001 IMN 
Cyclosporin A 5mg/kg/day, tapered over 
first 3 months then maintained at 
2mg/kg/day for 12 months (total 15 
months treatment) 
Average followup was 44.4 
+/- 9.6 months in 
cyclosporine group, 45.1 +/- 
5.6 months in control group 
Cattran et al. 
2001 
IMN + nephrotic syndrome, 
steroid resistant (failed to 
achieve remission after >8 weeks 
of prednisone treatment) 
Cyclosporine 3.5mg/kg/day divided, 
adjusted to trough levels of 125-225 
micrograms/L for 26 weeks, then tapered 
for 4 weeks; Prednisone 0.15mg/kg/day for 
26 weeks, then tapered for 8 weeks 78 weeks 
Cattran et al. 
1995 
IMN + nephrotic syndrome, 
worsening creatinine clearance 
over 12 months 
Cyclosporine 3.5 mg/kg/day divided BID, 
adjusted to achieve trough level of 110-170 
micrograms/L, continued for 12 months 
Average followup was 49 
months in cyclosporine 
group and 48 months in 
control group 
Alkylating agent vs. 
conservative/placebo 
Jha et al. 
2007 
IMN + nephrotic syndrome; 
excluded if systemic illness, DM, 
cancer, RVT, or 
immunosuppressants for 
>2months 
IV methylprednisolone 1g/day x3 days 
followed by 27 days PO prednisolone 
0.5mg/kg/day in months 1,3,5; PO 
cyclophosphamide 2mg/kg/day in months 
2,4,6 10 years 
Torres et al. 
2002 
IMN + renal insufficiency, from 
single hospital in Spain 
Prednisone 1 mg/kg/day for 1st month, 
0.5mg/kg/day for 2nd month, 0.5mg/kg 
QOD for 3rd-6th month; 0.15 mg/kg day 
Chlorambucil PO for 1st 14 weeks 
Average followup was 51.8 
+/- 36.5 months in 
chlorambucil group, 46.8 +/- 
37.5 months in control group 
Ponticelli et 
al. 1995 IMN + nephrotic syndrome 
1g IV methylprednisone daily x3days 
followed by 0.5mg/kg/day PO prednisone 
for 27 days in months 1,3,5; chlorambucil 
0.2mg/kg/day in months 2,4,6 10 years 
Falk et al. 
1992 
IMN + progressive disease 
(deteriorating renal function or 
persistent nephrotic syndrome 
with morbid complications) 
IV cyclophosphamide 0.5g/m2 with 3 days 
of pulse methylprednisolone, followed by 1 
mg/kg prednisone 
Average followup was 29.2 
+/- 17.1 months 
Jindal et al. 
1992 IMN + nephrotic syndrome Cyclophosphamide given >2 months 
Average followup was 83 +/- 
13 months in treated group 
and 64 +/- 7 months in 
control group 
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Table 2 
 
  
Authors, year Comparability of groups Dropouts, adherence, 
crossovers 
Selection bias Measurement bias 
Calcineurin inhibitor 
vs. alkylating agent 
Chen et al. 
2010 
Good randomization strategy; groups 
comparable in table 1 
Relatively high dropout rate: 
in tacrolimus group 6/39 
withdrew, in control group 
3/34 withdrew and 4/34 lost 
to followup; ITT analysis done 
Dropouts concerning- 
15% of tacrolimus group, 
21% of control group 
Patients and physicians 
aware of assignment, but 
endpoints judged at 
central location by 
masked investigators, 
histopathologists blinded 
Calcineurin inhibitor 
vs. 
conservative/placebo 
Praga et al. 
2007 
Appropriate randomization strategy;  
baseline differences between groups in 
age, proteinuria, eGFR, BP- would bias 
away from null 
Relatively high dropout rate: 
2/25 withrew from tacrolimus 
group and 1/23 from control; 
2/25 from tacrolimus group 
and 3/23 from control group 
lost to followup; ITT analysis 
done 
Dropouts concerning- 
16% of tacrolimus group, 
17% of control group 
Patients and physicians 
aware of assignment, not 
specified whether 
investigators measuring 
outcomes blinded 
Yao et al. 2001 
Don't describe how group assignment 
was made; groups mostly comparable 
in Table 1 (younger in cyclosporine 
group, but serum creatinine higher in 
control group) Not described 
Non-randomized; 
generally comparable on 
listed characteristics, but 
could be differences in 
unmeasured 
characteristics 
Objective definitions of 
endpoints provided, but 
not clear how measured 
or whether blinded 
Cattran et al. 
2001 
Good randomization strategy; groups 
similar in Table 1- greater proportion 
of males in cyclosporine group, but this 
would bias toward null 
Monitored adherence and 
found to be >90%; 4 dropped 
out prior to final endpoint (78 
weeks)- data from last 
followup assessment used  
Dropout rates 
acceptable, no significant 
source of selection bias 
apparent 
Patients masked but 
physicians were not, 
endpoints measured by 
central lab blinded to 
patient assignment 
Cattran et al. 
1995 
Appropriate randomization strategy; 
groups generally similar- some 
differences in age, gender, and 
creatinine clearance, but bias toward 
null None 
No significant source of 
selection bias apparent 
Patients masked but 
physicians were not 
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Table 2, continued 
 
  
Authors, year Comparability of groups Dropouts, adherence, 
crossovers 
Selection bias Measurement bias 
Alkylating agent vs. 
conservative/placebo 
Jha et al. 2007 
Appropriate randomization strategy, 
comparable in table 1 
7/53 from control and 4/51 
from experimental group lost 
to followup (excluded from 
analysis); 15 of 46 control 
patients were treated (2-
4.5yrs later)- crossover; ITT 
analysis done 
Some dropout/loss to 
followup; only crossover 
was from control to 
treatment, which would 
bias toward null 
Clearly defined endpoints 
but don't describe 
how/who measured, no 
blinding 
Torres et al. 
2002 
Not randomized (2 historical cohorts); 
generally similar in Table 1- difference 
in gender would bias away from null 
and difference in proteinuria would 
bias toward null None 
Non-randomized; 
generally comparable 
groups at baseline but 
different treatment 
periods/'eras' may be 
associated with other 
difference(s) in treatment 
or outcomes 
Use of medical records- 
effect of missing data 
could be non-differential; 
investigators not blinded 
to patient group 
Ponticelli et 
al. 1995 
Described in Ponticelli et al., N Engl J 
Med, 1989;320:8-13- unavailable from 
UNC.  Patients reported to be similar 
on a number of important 
variables/prognostic factors.   
10/39 from control and 9/42 
from chlorambucil group lost 
to followup, 3/39 from 
control and 1/42 from 
chlorambucil group died; for 
these patients, data from last 
observation used in analysis; 
ITT analysis done 
Randomized, groups 
reported to be 
comparable; significant 
loss to followup creates 
significant selection bias 
Clearly defined 
endpoints, but unclear 
how/who measured, 
whether blinded 
Falk et al. 
1992 
Appropriate randomization strategy; 
groups comparable in Table 1 except 
for race 
1 patient in 
cyclophosphamide group lost 
to followup after 1 yr, 1 
patient in control group 
dropped out                                     
Randomization and 
comparability generally 
ok, unclear whether race 
would have differential 
effect Not described 
Jindal et al. 
1992 
17 control patients (never received 
cyclophosphamide) matched for time 
period of biopsy, age at biopsy, 
nephrotic syndrome, and 2 peak serum 
creatinine concentrations to 9 treated 
patients in cohort; comparable in Table 
1 (more thromboembolic events in 
treated group, but bias toward null) 
1 patient in 
cyclophosphamide group 
dropped out after 13 months 
Non-randomized; 
controlled for some 
important 
variables/prognostic 
factors, but may be 
others that are different 
between treated subjects 
and controls 
Clearly defined outcomes, 
but not how or who 
measures not clear.  No 
blinding.  Control data 
from medical records 
(registry).   
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Table 2, continued 
 
Authors, year Potential 
confounders 
Results- magnitude and direction Overall internal validity, 
quality grade 
External validity Other 
Chen et al. 
2010 
Possibly 
differential 
dropout/loss to 
followup 
After 12 mos, remission rates similar- 79% in 
tacrolimus group and 69% in control group; 
eGFR without significant change in either group 
and without significant difference between 
groups 
poor  No significant 
differences between groups 
at 1 year, but relatively high 
dropout rate limits validity of 
findings 
Done in China, limits 
applicability to North 
American or Western 
populations 
Relatively short 
followup period (1 
yr) 
Praga et al. 
2007 
Some baseline 
differences in  
prognostic factors 
(age, proteinuria, 
eGFR, BP), 
favoring better 
outcome in 
tacrolimus group 
After 12 mos (end of full dose course), 72% of 
tacrolimus group and 22% of control group in 
remission (p<0.001); after 18 mos (end of 
taper), 76% of tacrolimus group and 30% of 
control group in remission (p=0.003) 
fair  Baseline differences 
between groups and 
dropouts may confound 
findings, but large 
magnitude of effect found 
Requirement of >9 mos 
of nephrotic syndrome 
and eGFR >50mL/min 
limits some of the 
population to whom this 
might be applied 
Relatively short 
followup (especially 
after stopping 
tacrolimus)- only 
followed patients 
through end of taper 
(18 mos) 
Yao et al. 
2001 
Indication for 
choosing whether 
to treat- may be 
differences 
between those 
treated and not 
After 15 mos (end of treatment course), 80% of 
cyclosporine group had achieved remission and 
13% of control group had achieved remission 
(p<0.05).  At time of last visit, there was no 
significant difference in remission between 
groups- 60% of cyclosporine group and 33% of 
control group were in remission (p=NS).   
poor  Non-randomized and 
group assignment not 
described, measurement not 
described  
Inclusion criteria not too 
limiting.  Performed in 
China, limits applicability 
to North American or 
Western populations.   
Longer followup 
than some other 
studies 
Cattran et al. 
2001 
 
After 26 wks, 75% of cyclosporine group and 
22% of control group in remission (p<0.001); 
after 52 wks, 46% of cyclosporine group and 
13% of control group in remission (p=0.004); 
after 78 wks, 39% of cyclosporine group and 
13% of control group in remission (p=0.007) 
good  Good study design 
intended to reduce potential 
sources of bias, clearly 
described, no major areas of 
concern; large magnitude of 
effect 
Inclusion criteria make 
findings  applicable to 
smaller population- 
failed 8 weeks of 
prednisone treatment, 
creatinine clearance 
>42mL/min, BP <135/85   
Cattran et al. 
1995   
12 mos after treatment initiation, rate of 
decline of Cr clearance in treated group 
improved from -2.43 to -0.73 mL/min/month 
(p<0.02), and in control group remained stable 
at -2.18 to -2.05 mL/min/month 
good  Overall good design, 
no bias apparent that would 
threaten findings 
Inclusion criteria not too 
limiting- include 
creatinine clearance >30, 
no serious co-morbid 
medical condition   
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Table 2, continued 
 
Authors, year Potential 
confounders 
Results- magnitude and direction Overall internal validity, 
quality grade 
External validity Other 
Jha et al. 
2007 
 
At 10 years' followup, 16 control and 34 
experimental pts achieved remission 
(p<0.0001); 65% of control and 89% of 
experimental pts achieved dialysis-free survival 
(p=0.016); 44% of control and 79% of 
experimental did not reach any of endpoints 
(death, ESRD, doubling of Cr) (p=0.0006).   
good  Some loss to followup 
is potential source of 
selection bias, but crossovers 
bias toward null and thus 
may result in 
underestimation of 
magnitude of effect 
Performed in India, may 
limit applicability of 
findings to North 
American or Western 
populations, though 
consistent with other 
large RCT 
Long followup of 
RCT provides 
valuable data not 
available in other 
studies; evaluation 
of ESRD, death, 
renal failure, and 
quality of life as 
endpoints is more 
meaningful 
Torres et al. 
2002 
Differences 
between historical 
cohorts- different 
overall 
treatment/care 
due to historical 
effect 
At last followup, no significant change in serum 
creatinine in treated group, significant increase 
in control group (p<0.001).  Probability of renal 
survival after 7 yrs was 90% in treated group, 
20% in control group (p<0.01); no significant 
difference between groups in patient survival at 
4 or 7 years of followup.   
poor  Limited by 
retrospective design and use 
of 2 historical cohorts from 
different time periods, 
though relatively large 
magnitude of effect may 
reflect true differences 
 
Longer followup is a 
strength, but small 
study.  Measured 
more 
meaningful/patient-
centered outcomes 
(renal survival, 
patient survival) 
Ponticelli et 
al. 1995 
Possibly 
differential loss to 
followup 
92% of treated did not progress to ESRD vs. 
60% of controls did not progress to ESRD, 
p=0.0038; by 10 years 88% of treated had a 
remission as first event vs. 47% of controls 
(p=0.0000) 
fair  Significant selection bias 
due to relatively high 
dropout/loss to followup.  
Large magnitude of effect 
indicates real findings in 
spite of any biases (though 
magnitude could be smaller) 
 
Long followup of 
RCT provides 
valuable data not 
available in other 
studies; evaluation 
of ESRD as an 
endpoint is more 
meaningful 
Falk et al. 
1992 
 
No significant difference in renal survival 
between groups 
fair  Measurement not clear 
or well-described, selection 
bias appears limited 
 
Measured a more 
meaningful 
outcome- renal 
survival.   
Jindal et al. 
1992 
Possibly sex, 
proteinuria, 
location/site of 
treatment (e.g. 
university hospital 
versus private 
nephrologist), 
other factors not 
controlled for 
At final followup, 12.5% of cyclophosphamide 
group had reached ESRD, compared to 58.8% of 
controls (p<0.05).   
poor  Significant potential 
for selection bias, 
measurement bias     
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